반복적인 131I rituximab 방사면역치료를 시행 받은 비호지킨 림프종 환자 군에서 종양 부위의 영상기반 방사선 흡수선량 평가와 임상적 의의 (Image-Based Assessment and Clinical Significance of Absorbed Radiation Dose to Tumor in Repeated High-Dose 131I Anti-CD20 Monoclonal Antibody (Rituximab) Radioimmunotherapy for Non-Hodgkin’s Lymphoma)

서지정보

· 발행기관 : 대한핵의학회
· 수록지 정보 : Nuclear Medicine and Molecular Imaging / 43권 / 1호 / 60 ~ 71페이지
· 저자명 : 변병현, 김경민, 우상근, 최태현, 강혜진, 오동현, 김병일, 천기정, 최창운, 임상무

초록

Purpose: We assessed the absorbed dose to the tumor (Dosetumor) by using pretreatment FDG-PET and whole-body (WB) planar images in repeated radioimmunotherapy (RIT) with 131I rituximab for NHL. Materials and Methods: Patients with NHL (n=4) were administered a therapeutic dose of 131I rituximab. Serial WB planar images after RIT were acquired and overlaid to the coronal maximum intensity projection (MIP) PET image before RIT. On registered MIP PET and WB planar images, 2D-ROIs were drawn on the region of tumor (n=7) and left medial thigh as background, and Dosetumor was calculated. The correlation between Dosetumor and the CT-based tumor volume change after RIT was analyzed. The differences of Dosetumor and the tumor volume change according to the number of RIT were also assessed. Results: The values of absorbed dose were 397.7±646.2cGy (53.0～2853.0cGy). The values of CT-based tumor volume were 11.3±9.1 cc (2.9～34.2cc), and the % changes of tumor volume before and after RIT were -29.8±44.3% (-100.0%～+42.5%), respectively. Dosetumor and the tumor volume change did not show the linear relationship (p>0.05). Dosetumor and the tumor volume change did not correlate with the number of repeated administration (p>0.05). Conclusion: We could determine the position and contour of viable tumor by MIP PET image. And, registration of PET and gamma camera images was possible to estimate the quantitative values of absorbed dose to tumor.

영어초록

Purpose: We assessed the absorbed dose to the tumor (Dosetumor) by using pretreatment FDG-PET and whole-body (WB) planar images in repeated radioimmunotherapy (RIT) with 131I rituximab for NHL. Materials and Methods: Patients with NHL (n=4) were administered a therapeutic dose of 131I rituximab. Serial WB planar images after RIT were acquired and overlaid to the coronal maximum intensity projection (MIP) PET image before RIT. On registered MIP PET and WB planar images, 2D-ROIs were drawn on the region of tumor (n=7) and left medial thigh as background, and Dosetumor was calculated. The correlation between Dosetumor and the CT-based tumor volume change after RIT was analyzed. The differences of Dosetumor and the tumor volume change according to the number of RIT were also assessed. Results: The values of absorbed dose were 397.7±646.2cGy (53.0～2853.0cGy). The values of CT-based tumor volume were 11.3±9.1 cc (2.9～34.2cc), and the % changes of tumor volume before and after RIT were -29.8±44.3% (-100.0%～+42.5%), respectively. Dosetumor and the tumor volume change did not show the linear relationship (p>0.05). Dosetumor and the tumor volume change did not correlate with the number of repeated administration (p>0.05). Conclusion: We could determine the position and contour of viable tumor by MIP PET image. And, registration of PET and gamma camera images was possible to estimate the quantitative values of absorbed dose to tumor.

참고자료

· 없음